TRACERx Study Highlights Advances in ctDNA Detection for Cancer Monitoring
At the AACR meeting, Ultima Genomics presented new findings from the TRACERx study, showcasing the capabilities of their ppmSeq technology in detecting minimal residual disease (MRD) in cancer patients. The study, one of the largest of its kind, focuses on tracking cancer evolution and resistance to treatment. Using ppmSeq, researchers achieved high sensitivity in detecting circulating tumor DNA (ctDNA) at very low concentrations, which is crucial for assessing treatment effectiveness and relapse risk. 
